Biotech Soars On Material Transfer Agreement - InvestingChannel

Biotech Soars On Material Transfer Agreement

A New York-based biotech company is turning heads on Tuesday after it announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense’s military and veterans adaptive platform clinical trial for PTSD.

Traders were quick to snatch up shares of Seelos Therapeutics Inc. (Nasdaq:SEEL), pushing the price of this micro cap up to $0.5536/share (+191.37%) at the early session high. This move  could be indicative of a potential breakout for this stock in sessions to come!

Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address significant unmet needs in the Central Nervous System (CNS) disorders and other rare disorders.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View the original article on AllPennyStocks.com

]]>

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire